Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00254423 · ClinicalTrials.gov registry record · Phase 2
Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
NCT00254423: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00254423 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 150 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00254423, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if BMS-354825 (dasatinib) can help to control CML in chronic phase. The safety of this drug will also be studied.
Interventions
- DRUG Dasatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2005-11-08 |
| Est. Completion | 2025-03-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00254423
The ClinicalTrials.gov registry entry for NCT00254423 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dasatinib is the first listed.
NCT00254423 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00254423 about?
NCT00254423 is a clinical study titled "Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia". The goal of this clinical research study is to learn if BMS-354825 (dasatinib) can help to control CML in chronic phase. The safety of this drug will also be studied.
What is the current status of trial NCT00254423?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2005-11-08. Estimated completion is 2025-03-14.
What interventions are being tested in trial NCT00254423?
The interventions under investigation include: Dasatinib (DRUG).
Who is sponsoring clinical trial NCT00254423?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.